Le Lézard
Classified in: Covid-19 virus
Subject: Product/Service

Easterly Government Properties Announces Lease Commencement for 59,690 SF FDA Laboratory Re-Development in Lenexa, KS


Easterly Government Properties, Inc. (NYSE: DEA) ("Easterly"), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, announced today that the lease has commenced at the newly re-developed 59,690-square foot U.S. Food and Drug Administration (FDA) laboratory located in Lenexa, Kansas ("FDA - Lenexa").

As previously announced, Easterly was awarded the lease to re-develop the new FDA laboratory, one of 13 regional laboratories strategically located throughout the country. The approximately $67 million project achieved substantial completion in the third quarter of 2020, a quarter earlier than anticipated, and a 20-year lease term has commenced with the General Services Administration (GSA) for the beneficial use of the FDA.

"It was our pleasure to work alongside the U.S. Government and deliver the latest state-of-the-art laboratory for the beneficial use of the FDA," said Michael Ibe, Easterly's Vice Chairman and EVP of Development and Acquisitions. "Even with a challenging COVID-19 backdrop, Easterly not only maintained but accelerated its schedule and delivered a mission critical space to this highly important government agency with a brand-new 20-year lease."

The FDA - Lenexa laboratory is a relocation of the former Kansas City District Laboratory and features a number of upgraded capabilities in order for the FDA to effectively conduct its mission. With a significant increase in size over its former location, the new state-of-the-art laboratory offers services through the following laboratory sections: the Total Diet and Pesticides Research Center (TDPRC), Pesticides analysis, Chemotherapeutics / LC-MS Poison screening, Mycotoxins analysis, Drugs and Dietary Supplements analysis, Dioxins analysis, Metals / Elemental Specialization analysis, and Laboratory Administration.

"Mike Ibe and his development team have mastered the art behind the procurement, design, construction and delivery of superior laboratory space for the United States Government," said Meghan Baivier, Easterly's Chief Financial and Operating Officer. "We believe the team's ability to effectively execute and ultimately deliver accretion to our shareholders through a re-development project like this is second to none."

FDA - Lenexa is the second FDA re-development project in the Easterly portfolio, following last year's delivery of FDA - Alameda and preceding the anticipated future delivery of FDA - Atlanta.

About Easterly Government Properties, Inc.

Easterly Government Properties, Inc. (NYSE: DEA) is based in Washington, D.C., and focuses primarily on the acquisition, development and management of Class A commercial properties that are leased to the U.S. Government. Easterly's experienced management team brings specialized insight into the strategy and needs of mission-critical U.S. Government agencies for properties leased to such agencies either directly or through the U.S. General Services Administration (GSA). For further information on the company and its properties, please visit www.easterlyreit.com.


These press releases may also interest you

at 18:00
Quanta X Technology, the parent company of QuantaDose, CEO Katie Webb suggests, "Anyone in Santa's shoes gifting a UVC device to a friend or family member needs to make sure the UV-C device is real, and they also need to understand the potential...

at 17:00
63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ?6 months of follow-up, 83% have ongoing responses...

at 15:05
ImmunoGen Inc. , a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new safety and efficacy findings from the expansion phase of the Phase 1/2 study of IMGN632 in patients with...

at 15:00
Amgen today announced the first presentation of clinical safety and efficacy data from the Phase 1 study of AMG 701 in heavily pre-treated patients with relapsed/refractory multiple myeloma (R/R MM). AMG 701 is an investigational half-life extended...

at 14:09
The Correctional Service of Canada (CSC) has over 4500 volunteers who dedicate their time and energy to work with and support the offenders in our care and custody. As we mark International Volunteer Day, CSC would like to take this opportunity to...

at 12:46
Three studies being presented during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to-treat blood disorders and cancers....



News published on 29 october 2020 at 09:10 and distributed by: